Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreNo recent work listed

Gabriella Macchia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0529-201X; OpenAlex author ID A5070096760. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 4 papers · 2020: 3 papers · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper

Papers 18

  1. Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PA… Co-author DOI 10.3390/curroncol30060427↗
  2. Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis. Co-author DOI 10.1159/000525945↗
  3. Pain Relief after Stereotactic Radiotherapy of Pancreatic Adenocarcinoma: An Updated Systematic Review. Co-author DOI 10.3390/curroncol29040214↗
  4. Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients. Co-author DOI 10.1007/s00432-020-03411-7↗
  5. Correction to: Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients. Co-author DOI 10.1007/s00432-020-03439-9↗
  6. Definition of Local Recurrence Site in Resected Pancreatic Adenocarcinoma: A Multicenter Study (DOLORES-1). Co-author DOI 10.3390/cancers13123051↗
  7. Automated treatment planning as a dose escalation strategy for stereotactic radiation therapy in pancreatic cancer. Co-author DOI 10.1002/acm2.13025↗
  8. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1). Co-author DOI 10.1002/cam4.3330↗
  9. Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). Co-author DOI 10.21873/anticanres.13975↗
  10. Radiotherapy of pancreatic cancer in older patients: A systematic review. Co-author DOI 10.1016/j.jgo.2018.09.007↗
  11. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Co-author DOI 10.1016/j.tranon.2018.08.017↗
  12. Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a m… Co-author DOI 10.1080/0284186x.2018.1546899↗
  13. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. Co-author DOI 10.1186/s12885-019-5790-2↗
  14. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief. First author DOI 10.2147/jpr.s167994↗
  15. Patterns of radiotherapy practice for pancreatic cancer: Results of the Gastrointestinal Radiation Oncology Study Group multi-institutional survey. Co-author DOI 10.3892/or.2015.3955↗
  16. Inter-observer variability of clinical target volume delineation in radiotherapy treatment of pancreatic cancer: a multi-institutional contouring experience. First author DOI 10.1186/1748-717x-9-198↗
  17. Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-012-2767-7↗
  18. Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer. Co-author DOI 10.1186/1748-717x-7-86↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessio Giuseppe Morganti · 18 shared papers, 2012–2023 · strength 1.52
  2. Milly Buwenge · 12 shared papers, 2018–2023 · strength 1.20
  3. Francesco Cellini · 12 shared papers, 2018–2023 · strength 1.19
  4. Gian Carlo Mattiucci · 11 shared papers, 2013–2023 · strength 0.89
  5. Alessandra Arcelli · 9 shared papers, 2018–2023 · strength 0.86
  6. Savino Cilla · 9 shared papers, 2012–2023 · strength 0.84
  7. Vincenzo Valentini · 10 shared papers, 2012–2022 · strength 0.77
  8. S. Cammelli · 7 shared papers, 2018–2022 · strength 0.68
  9. Lidia Strigari · 3 shared papers, 2021–2023 · strength 0.38
  10. Nicola Simoni · 4 shared papers, 2019–2023 · strength 0.37
  11. Mariacristina Di Marco · 4 shared papers, 2019–2023 · strength 0.37
  12. Michele Fiore · 4 shared papers, 2015–2023 · strength 0.35
  13. Renzo Mazzarotto · 3 shared papers, 2020–2023 · strength 0.30
  14. Sergio Alfieri · 4 shared papers, 2013–2022 · strength 0.29
  15. A. Sainato · 4 shared papers, 2014–2021 · strength 0.24
  16. Domenico Genovesi · 4 shared papers, 2014–2021 · strength 0.24
  17. Luca Boldrini · 2 shared papers, 2021 · strength 0.24
  18. Riccardo Casadei · 3 shared papers, 2019–2020 · strength 0.22
  19. Lorenzo Fuccio · 3 shared papers, 2018–2019 · strength 0.21
  20. Luciana Caravatta · 4 shared papers, 2012–2019 · strength 0.17
  21. Elisa Grassi · 2 shared papers, 2018–2020 · strength 0.17
  22. William F. Regine · 2 shared papers, 2019 · strength 0.14
  23. Felipe Ángel Calvo · 2 shared papers, 2019 · strength 0.14
  24. Robert Clell Miller · 2 shared papers, 2019 · strength 0.14
  25. Francesco Minni · 2 shared papers, 2019 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.